Published 17th October 2017

Inivata highlights new clinical data on InVision™

Inivata, a global clinical cancer genomics company utilizing an industry-leading liquid biopsy platform to transform patient care, will present new clinical data from its collaboration with Dana-Farber Cancer Institute at the World Conference on Lung Cancer (WCLC).

The study involved a blind retrospective evaluation of Inivata’s InVision ctDNA liquid biopsy analysis  to characterize and monitor the molecular profile of advanced non-small cell lung cancer (NSCLC).

The technology was shown to detect a full range of genotypes, including gene rearrangements and was able to detect ALK and ROS1 fusions with high sensitivity. 

The data will be presented by first author Dr. Nicolas Guibert at 09:30 on Wednesday 18 October in the Biology/Pathology Poster Session in Exhibit Hall B+C.

Read Inivata's statement